U.S. countermeasures In April 2016, the Obama administration announced new tax rules to increase the threshold for a U.S. corporate tax inversion to be considered a "foreign company", and thus escape U.S. taxation. The new rules were directly designed to block the proposed $160 billion merger of U.S.–based Pfizer and Irish–based Allergan, which would have been the largest corporate tax inversion in history. The rule changes worked by disregarding acquisitions a target (e.g. Allergan), had made in the 3 years prior to the inversion, in meeting the requirement for the target to be 40% of the merged group. In December 2017, the Trump administration's U.S. Tax Cuts and Jobs Act (TCJA) overhauled the U.S. tax-code and replicated many of the changes the UK made to their tax-code in 2009–2012 to successfully combat inversions (see below). In particular, the TCJA moved the U.S to a hybrid–"territorial tax" system, reduced the headline rate from 35% to 21% and introduced a new GILTI–FDII–BEAT regime designed to remove incentives for U.S. multinationals to execute corporate tax inversions to Ireland. In December 2017, U.S technology firm Vantiv, the world's largest payment processing company, confirmed it had abandoned its plan to execute a corporate tax inversion to Ireland. In Q1 2018, Pfizer disclosed that post the TCJA its global tax rate for 2019 would be 17%, similar to the circa 15–16% 2019 tax rate of past U.S. corporate tax inversions to Ireland, Eaton, Allergan, and Medtronic. In March 2018, the Head of Life Sciences in Goldman Sachs, Jami Rubin, stated that: "Now that [U.S.] corporate tax reform has passed, the advantages of being an inverted company are less obvious". In August 2018, U.S. multinational Afilias, who had been headquartered in Ireland since 2001, announced that as a result of the TCJA, it was moving back to the U.S. , there have been no further U.S. corporate tax inversions to Ireland since the 2016–2017 rule changes by the Obama, and the Trump administrations. Apple's inversion Apple's Q1 2015 re-structure of their Irish BEPS tool, is considered by some economists to be a quasi–inversion. Whereas Apple did not relocate its corporate headquarters to Ireland like Pfizer tried to do with Allergan, Apple was able to use the CAIA BEPS tool to legally re-locate $300 billion of IP, equivalent to all of Apple's non–U.S. business, to Ireland. While the Obama administration blocked the proposed $160 billion Pfizer–Allergan tax inversion